business
Insulet Corporation Q1 2026 Earnings Call Summary
Key takeaways
- International performance exceeded expectations with 45% growth, fueled by record new customer starts in established markets like the U.K. and favorable price/mix from DASH-to-Omnipod 5 conversion.
- U.S. growth of 28% was supported by strong type 2 momentum, though results were tempered by higher-than-normal Q1 seasonality related to deductible resets.
- Management attributes market leadership to a first-mover advantage in the pharmacy channel and the inherent complexity of manufacturing disposable tubeless devices at scale.
Insulet Corporation Q1 2026 Earnings Call Summary Moby Intelligence Thu, May 7, 2026 at 12:00 AM GMT+7 3 min read PODD Insulet Corporation Q1 2026 Earnings Call Summary - Moby Strategic Performance Drivers Achieved 30% constant currency revenue growth, driven by robust international expansion and continued adoption of Omnipod 5 across type 1 and type 2 segments.
International performance exceeded expectations with 45% growth, fueled by record new customer starts in established markets like the U.K. and favorable price/mix from DASH-to-Omnipod 5 conversion.
U.S. growth of 28% was supported by strong type 2 momentum, though results were tempered by higher-than-normal Q1 seasonality related to deductible resets.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Investing.com
Earnings call transcript: TGS Q1 2026 sees 12.5% income growth
Investing.com
Earnings call transcript: Timbercreek Financial misses Q1 2026 estimates
Investing.com
Earnings call transcript: Hut 8 Q1 2026 reports major revenue growth
Investing.com
Earnings call transcript: GXO Logistics reports Q1 2026 earnings beat, raises guidance
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop